



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	338032	Neuro A
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Biomedica Nutraceuticals Pty Ltd	
<b>Postal Address</b>	PO Box 7052, ALEXANDRIA, NSW, 2015 Australia	
<b>ARTG Start Date</b>	17/06/2020	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Neuro A

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	17/06/2020
---------------------	-------------------------	-----------------------	------------

### Permitted Indications

Maintain/support general health and wellbeing  
Traditionally used in Western herbal medicine to decrease/reduce/relieve restlessness/excess nervous energy  
Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of stress  
Traditionally used in Western herbal medicine to decrease/reduce/relieve nervous tension/unrest  
Maintain/support brain function  
Aid/assist/helps synthesis of neurotransmitters  
Traditionally used in Western herbal medicine to calmative/nervous system relaxant  
Traditionally used in Western herbal medicine to nervine/support nervous system  
Maintain/support nervous system function  
Support healthy emotional/mood balance  
Traditionally used in Western herbal medicine to support healthy emotional/mood balance  
Traditionally used in Western herbal medicine to decrease/reduce/relieve sleeplessness

### Indication Requirements

Label statement: If symptoms persist, talk to your health professional.  
Product presentation must not imply or refer to mental illnesses, disorders or conditions.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

No Warnings included on Record



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Lavandula angustifolia flower Oil essential</b>	<b>27 mg</b>
<b>Melissa officinalis herb Extract dry concentrate</b>	<b>130 mg</b>
Equivalent: Melissa officinalis (Dry)	1.3 g
<b>pyridoxal 5-phosphate monohydrate</b>	<b>7.84 mg</b>
Equivalent: pyridoxine	5 mg
<b>pyridoxine hydrochloride</b>	<b>6.08 mg</b>
Equivalent: pyridoxine	5 mg
<b>Scutellaria lateriflora herb Extract dry concentrate</b>	<b>250 mg</b>
Equivalent: Scutellaria lateriflora (Dry)	1 g
<b>zinc amino acid chelate</b>	<b>10 mg</b>
Equivalent: zinc	2 mg

**Other Ingredients (Excipients)**

colloidal anhydrous silica  
hypromellose  
magnesium stearate  
maltodextrin  
microcrystalline cellulose  
silicon dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary